Ovarian cancer laboratory findings: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Laboratory findings
Sabawoon Mirwais (talk | contribs)
CMEAdmin, CMEUser, Bureaucrats, bureaucrats, exportpages, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
4,937 edits
No edit summary
 
(19 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Ovarian cancer}}
{{CMG}}; {{AE}} {{Hudakarman}}
==Overview==
The evaluation includes [[laboratory]] work, [[imaging]] and [[surgical]] exploration for the definite [[diagnosis]]. Routine lab work includes CBC and CMP, Serum biomarkers of of [[epithelial ovarian cancer]] includes [[CA125]], HE4, OVA1. Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer include [[alpha-fetoprotein]], [[human chorionic gonadotropin]], [[lactate dehydrogenase]], [[estradiol]], [[Inhibin]], [[testosterone]], [[androstenedione]], dehydroepiandrostenedione, [[anti-Müllerian hormone]].
==Laboratory Findings==


{{Ovarian cancer}}
* Patients with [[ovarian cancer]] can present [[Acute|acutely]] or [[Subacute|sub-acutely]]
* If there is clinical suspicion of [[malignancy]], the evaluation includes [[Laboratory|laboratory work]], [[imaging]] and [[surgical]] exploration for the definite [[diagnosis]]
*Routine lab work
**[[CBC|complete blood count (CBC]])
**Complete metabolic panel (CMP)
*Serum [[biomarkers]] of [[epithelial ovarian cancer]] (EOC):<ref name="pmid11369781">{{cite journal| author=Yin BW, Lloyd KO| title=Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | journal=J Biol Chem | year= 2001 | volume= 276 | issue= 29 | pages= 27371-5 | pmid=11369781 | doi=10.1074/jbc.M103554200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11369781  }} </ref><ref name="pmid15781627">{{cite journal| author=Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR et al.| title=Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. | journal=Cancer Res | year= 2005 | volume= 65 | issue= 6 | pages= 2162-9 | pmid=15781627 | doi=10.1158/0008-5472.CAN-04-3924 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15781627  }} </ref><ref name="pmid6310399">{{cite journal| author=Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H et al.| title=A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. | journal=N Engl J Med | year= 1983 | volume= 309 | issue= 15 | pages= 883-7 | pmid=6310399 | doi=10.1056/NEJM198310133091503 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6310399  }} </ref><ref name="pmid2651469">{{cite journal| author=Jacobs I, Bast RC| title=The CA 125 tumour-associated antigen: a review of the literature. | journal=Hum Reprod | year= 1989 | volume= 4 | issue= 1 | pages= 1-12 | pmid=2651469 | doi=10.1093/oxfordjournals.humrep.a136832 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2651469  }} </ref><ref name="pmid15313933">{{cite journal| author=Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al.| title=Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. | journal=Cancer Res | year= 2004 | volume= 64 | issue= 16 | pages= 5882-90 | pmid=15313933 | doi=10.1158/0008-5472.CAN-04-0746 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15313933  }} </ref>
**[[CA125]]
*** Considered the best for [[ovarian cancer]] detection, [[therapeutic]] monitoring, and detection of the tumor recurrence
***[[Postmenopausal]] woman: should be measured
***[[Premenopausal]] woman: should be measured only if [[ultrasonogram]] shows highly suspicious malignant mass
** HE4
***[[CA125]] and HE4 are used together to increase the [[sensitivity]] and [[specificity]] of [[ovarian cancer]] detection
***Risk of Ovarian Malignancy Algorithm ([[ROMA]]) is used to decide if the patient has a high risk or low-risk [[malignant]] disease based on:
****[[CA125]] and HE4 levels
****[[Menopausal]] status of the woman
** OVA1
***
*Serum [[biomarkers]] of the [[germ cell]] and [[Sexcord/ stromal ovarian tumors|sex cord-stromal]] [[ovarian cancer]]:<ref name="JashnaniHegde2013">{{cite journal|last1=Jashnani|first1=KusumD|last2=Hegde|first2=ChandrashekarV|last3=Munot|first3=ShrutikaP|title=Alfa-fetoprotein secreting ovarian sex cord-stromal tumor|journal=Indian Journal of Pathology and Microbiology|volume=56|issue=1|year=2013|pages=54|issn=0377-4929|doi=10.4103/0377-4929.116152}}</ref>
**AFP: [[alpha-fetoprotein]]
**hCG: [[human chorionic gonadotropin]]
**LDH: [[lactate dehydrogenase]]
**E2: [[estradiol]]
**[[Inhibin]]
**Testost: [[testosterone]]
**Andro:  [[androstenedione]]
**DHEA: dehydroepiandrostenedione
**AMH: [[anti-Müllerian hormone]]


Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
*The gene for [[CA125]] was cloned in 2001 and is called MUC16.<ref name="pmid11369781">{{cite journal| author=Yin BW, Lloyd KO| title=Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | journal=J Biol Chem | year= 2001 | volume= 276 | issue= 29 | pages= 27371-5 | pmid=11369781 | doi=10.1074/jbc.M103554200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11369781 }} </ref>
*[[Radioimmunoassay]] using a [[monoclonal antibody]] to monitor the course of [[epithelial ovarian cancer]].<ref name="pmid6310399">{{cite journal| author=Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H et al.| title=A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. | journal=N Engl J Med | year= 1983 | volume= 309 | issue= 15 | pages= 883-7 | pmid=6310399 | doi=10.1056/NEJM198310133091503 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6310399  }} </ref>
*[[CA125]] and the second generation test (CA125 II) are both clinically equivalent.<ref name="pmidPMID 16690492">{{cite journal| author=Mongia SK, Rawlins ML, Owen WE, Roberts WL| title=Performance characteristics of seven automated CA 125 assays. | journal=Am J Clin Pathol | year= 2006 | volume= 125 | issue= 6 | pages= 921-7 | pmid=PMID 16690492 | doi=10.1309/NBA3-12W0-LANR-XYH9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16690492 }} </ref>


* Patients with ovarian cancer can present acutely or sub-acutely
* If there is clinical suspicion of malignancy, the evaluation include laboratory work, imaging and surgical exploration for the definite diagnosis
*CBC
*CBP
*Serum biomarkers:
** CA 125
*** Postmenopausal woman: should be measured
*** Premenopausal woman: should be measured only if US shows highly suspicious malignant mass
*


== References ==
== References ==

Latest revision as of 22:37, 8 October 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer laboratory findings

CDC on Ovarian cancer laboratory findings

Ovarian cancer laboratory findings in the news

Blogs on Ovarian cancer laboratory findings

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.

Overview

The evaluation includes laboratory work, imaging and surgical exploration for the definite diagnosis. Routine lab work includes CBC and CMP, Serum biomarkers of of epithelial ovarian cancer includes CA125, HE4, OVA1. Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer include alpha-fetoprotein, human chorionic gonadotropin, lactate dehydrogenase, estradiol, Inhibin, testosterone, androstenedione, dehydroepiandrostenedione, anti-Müllerian hormone.

Laboratory Findings


References

  1. ↑ 1.0 1.1 Yin BW, Lloyd KO (2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". J Biol Chem. 276 (29): 27371–5. doi:10.1074/jbc.M103554200. PMID 11369781.
  2. ↑ Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR; et al. (2005). "Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas". Cancer Res. 65 (6): 2162–9. doi:10.1158/0008-5472.CAN-04-3924. PMID 15781627.
  3. ↑ 3.0 3.1 Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H; et al. (1983). "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N Engl J Med. 309 (15): 883–7. doi:10.1056/NEJM198310133091503. PMID 6310399.
  4. ↑ Jacobs I, Bast RC (1989). "The CA 125 tumour-associated antigen: a review of the literature". Hum Reprod. 4 (1): 1–12. doi:10.1093/oxfordjournals.humrep.a136832. PMID 2651469.
  5. ↑ Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ; et al. (2004). "Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer". Cancer Res. 64 (16): 5882–90. doi:10.1158/0008-5472.CAN-04-0746. PMID 15313933.
  6. ↑ Jashnani, KusumD; Hegde, ChandrashekarV; Munot, ShrutikaP (2013). "Alfa-fetoprotein secreting ovarian sex cord-stromal tumor". Indian Journal of Pathology and Microbiology. 56 (1): 54. doi:10.4103/0377-4929.116152. ISSN 0377-4929.
  7. ↑ Mongia SK, Rawlins ML, Owen WE, Roberts WL (2006). "Performance characteristics of seven automated CA 125 assays". Am J Clin Pathol. 125 (6): 921–7. doi:10.1309/NBA3-12W0-LANR-XYH9. PMID 16690492 PMID 16690492 Check |pmid= value (help).

Template:WH

Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Ovarian_cancer_laboratory_findings&oldid=1583730"